Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1994 1
1998 1
2000 1
2002 2
2003 1
2005 3
2007 5
2009 3
2010 3
2011 1
2012 1
2013 4
2014 1
2015 2
2016 6
2017 3
2018 2
2019 4
2020 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Perrotta C, Chahla J, Badariotti G, Ramos J. Perrotta C, et al. Cochrane Database Syst Rev. 2020 May 6;5(5):CD005259. doi: 10.1002/14651858.CD005259.pub4. Cochrane Database Syst Rev. 2020. PMID: 32374919 Free PMC article.
MAIN RESULTS: This update adds four new studies, bringing the total of included studies to eight and involving 3818 adult participants with no history of thromboembolic disease undergoing KA. Studies compared daily subcutaneous (sc) low-molecular-weight heparin (LMWH) vers …
MAIN RESULTS: This update adds four new studies, bringing the total of included studies to eight and involving 3818 adult participants with …
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Jordan F, Quinn TJ, McGuinness B, Passmore P, Kelly JP, Tudur Smith C, Murphy K, Devane D. Jordan F, et al. Cochrane Database Syst Rev. 2020 Apr 30;4(4):CD011459. doi: 10.1002/14651858.CD011459.pub2. Cochrane Database Syst Rev. 2020. PMID: 32352165 Free PMC article.
We identified one trial (19,114 participants) comparing low-dose aspirin (100 mg once daily) to placebo. Participants were aged 70 years or older with no history of dementia, cardiovascular disease or physical disability. ...One trial (2528 participants) investigated the c …
We identified one trial (19,114 participants) comparing low-dose aspirin (100 mg once daily) to placebo. Participants were aged 70 years or …
No Difference Between Low- and Regular-dose Aspirin for Venous Thromboembolism Prophylaxis After THA.
Faour M, Piuzzi NS, Brigati DP, Klika AK, Mont MA, Barsoum WK, Higuera CA. Faour M, et al. Clin Orthop Relat Res. 2019 Feb;477(2):396-402. doi: 10.1097/CORR.0000000000000613. Clin Orthop Relat Res. 2019. PMID: 30624322 Free PMC article.
During the study period, aspirin was prescribed as a monotherapy for VTE prophylaxis after surgery in low-risk patients (no history of VTE, recent orthopaedic surgery, hypercoagulable state, history of cardiac arrhythmia requiring anticoagulation, or receiving antic …
During the study period, aspirin was prescribed as a monotherapy for VTE prophylaxis after surgery in low-risk patients (no history o …
Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis.
Major RW, Oozeerally I, Dawson S, Riddleston H, Gray LJ, Brunskill NJ. Major RW, et al. Atherosclerosis. 2016 Aug;251:177-182. doi: 10.1016/j.atherosclerosis.2016.06.013. Epub 2016 Jun 10. Atherosclerosis. 2016. PMID: 27341534
Inclusion criteria were adult subjects with non-endstage chronic kidney disease (CKD) and no history of cardiovascular disease. The co-primary outcomes were major cardiovascular events and all-cause mortality. ...
Inclusion criteria were adult subjects with non-endstage chronic kidney disease (CKD) and no history of cardiovascular disease. The c …
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
Pignone M, Williams CD. Pignone M, et al. Nat Rev Endocrinol. 2010 Nov;6(11):619-28. doi: 10.1038/nrendo.2010.169. Epub 2010 Sep 21. Nat Rev Endocrinol. 2010. PMID: 20856266 Free PMC article. Review.
Aspirin is effective for the prevention of cardiovascular events in patients with a history of vascular disease, as so-called secondary prevention. In general populations with no history of previous myocardial infarction or stroke, aspirin also seems useful for prim …
Aspirin is effective for the prevention of cardiovascular events in patients with a history of vascular disease, as so-called seconda …
Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease: Use Patterns and Impact Across Race and Ethnicity in the Southern Community Cohort Study.
Fernandez-Jimenez R, Wang TJ, Fuster V, Blot WJ. Fernandez-Jimenez R, et al. J Am Heart Assoc. 2019 Dec 17;8(24):e013404. doi: 10.1161/JAHA.119.013404. Epub 2019 Dec 11. J Am Heart Assoc. 2019. PMID: 31822218 Free PMC article.
Methods and Results Overall, 65 231 non-Hispanic black and white people aged 40 to 79 years with no history of CVD enrolled from 2002 through 2009 in the SCCS (Southern Community Cohort Study). ...
Methods and Results Overall, 65 231 non-Hispanic black and white people aged 40 to 79 years with no history of CVD enrolled from 2002 …
Underuse of beta-blockers by patients with COPD and co-morbid acute coronary syndrome: A nationwide follow-up study in New Zealand.
Parkin L, Quon J, Sharples K, Barson D, Dummer J. Parkin L, et al. Respirology. 2020 Feb;25(2):173-182. doi: 10.1111/resp.13662. Epub 2019 Aug 11. Respirology. 2020. PMID: 31401813 Free article.
Patients with higher COPD severity were less likely to receive a beta-blocker than those with lower severity, as were those with no history of previous ACS and/or heart failure. CONCLUSION: Use of beta-blockers following an ACS admission was much lower than expected based …
Patients with higher COPD severity were less likely to receive a beta-blocker than those with lower severity, as were those with no histo
Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma.
Mallonee S, Daniels CG, Mold JW, Cline TL. Mallonee S, et al. J Okla State Med Assoc. 2010 Jul;103(7):254-60. J Okla State Med Assoc. 2010. PMID: 20821923
Oklahoma Behavioral Risk Factor Surveillance System (BRFSS) data were used to determine past history of CHD, risk factors for CHD and stroke, and aspirin use among persons 45 years and older. ...RESULTS: Between 2005-2008, 14.8% of Oklahomans 45 years of age and older repo …
Oklahoma Behavioral Risk Factor Surveillance System (BRFSS) data were used to determine past history of CHD, risk factors for CHD and …
Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
Dad T, Tighiouart H, Joseph A, Bostom A, Carpenter M, Hunsicker L, Kusek JW, Pfeffer M, Levey AS, Weiner DE. Dad T, et al. Am J Kidney Dis. 2016 Aug;68(2):277-286. doi: 10.1053/j.ajkd.2016.01.019. Epub 2016 Mar 2. Am J Kidney Dis. 2016. PMID: 26947217 Free PMC article. Clinical Trial.
LIMITATIONS: We did not examine dose or continued use of aspirin after randomization. CVD history is dependent on participant report at baseline. Aspirin use was non-randomly assigned. CONCLUSIONS: Aspirin use is not associated with reduced risk for incident CVD, all-cause …
LIMITATIONS: We did not examine dose or continued use of aspirin after randomization. CVD history is dependent on participant report …
Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer.
Ye S, Lee M, Lee D, Ha EH, Chun EM. Ye S, et al. JAMA Netw Open. 2019 Mar 1;2(3):e190185. doi: 10.1001/jamanetworkopen.2019.0185. JAMA Netw Open. 2019. PMID: 30821825 Free PMC article.
Eligible participants (n = 12 969 400) were people aged 40 to 84 years who had undergone national health screening between 2009 and 2010 and had no history of lung cancer between 2006 and 2010 and no standard-dose aspirin use for 6 months between 2002 and 2010. ...
Eligible participants (n = 12 969 400) were people aged 40 to 84 years who had undergone national health screening between 2009 and 2010 and …
43 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page